We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




AI-Powered Prostate Cancer Diagnosis Tool Accurately Identifies and Classifies Tumors

By LabMedica International staff writers
Posted on 14 Mar 2023
Print article
Image: QAi Prostate is an advanced AI-powered prostate cancer diagnosis tool for pathologists (Photo courtesy of Qritive)
Image: QAi Prostate is an advanced AI-powered prostate cancer diagnosis tool for pathologists (Photo courtesy of Qritive)

Prostate adenocarcinoma is the most prevalent form of prostate cancer, representing around 90% of all prostate cases, and is also the second most commonly occurring cancer in men, demonstrating a steady increase in prevalence worldwide. Now, a powerful tool to detect prostatic adenocarcinoma leverages advanced machine learning algorithms to accurately identify and classify malignant and benign areas in prostate biopsies, thereby improving diagnostic accuracy and patient outcomes.

Qritive (Singapore) has launched a new AI (Artificial Intelligence) module, QAi Prostate, for prostate cancer diagnosis that uses advanced machine learning algorithms to analyze whole slide images of prostate core needle biopsies, identify prostatic adenocarcinoma region, and segment and classify them into benign and malignant areas. QAi Prostate uses whole slide images as well as regions of interest (ROI) for screening adenocarcinoma. QAi Prostate provides a detailed summary of the tumor size and percentage for each slide or ROI, allowing pathologists to quickly make more informed and accurate diagnoses, thus reducing the time to treatment for patients.

QAi Prostate has been built using a comprehensive dataset that has passed through extensive testing and validation procedures to ensure it meets the required clinical metrics and reliability standards. It is compatible with all standard digital pathology systems and can be easily integrated into existing workflows using Open API interface through a customizable middleware. It allows for secured communication using standard SSL encryption and the middleware as a single point of entry with role-based access to ensure advanced security and compliance. QAi Prostate is currently not approved by the FDA or CE marked and can be deployed for research use or as laboratory developed test only.

"We are excited to introduce this new AI module for prostate cancer diagnosis," said Dr. Kaveh Taghipour, CTO of Qritive. "QAi Prostate has been developed using millions of data points and thousands of hours of expert knowledge. This technology has the potential to improve the accuracy and speed of prostate cancer diagnosis significantly, leading to better outcomes for patients."

Related Links:
Qritive 

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Rickettsia Conorii Assay
RICKETTSIA CONORII ELISA

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Molecular Diagnostics

view channel
Image: Researchers have found the first evidence of testing for the alpha-synuclein protein in blood samples via seed amplification assay (Photo courtesy of Shutterstock)

Blood Test to Detect Alpha-Synuclein Protein Could Revolutionize Parkinson's Disease Diagnostics

Currently, Parkinson's disease (PD) is identified through clinical diagnosis, typically at a later stage in the disease's progression. There is a pressing need for an objective and quantifiable biomarker... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Immunology

view channel
Image: The blood test measures lymphocytes  to guide the use of multiple myeloma immunotherapy (Photo courtesy of 123RF)

Simple Blood Test Identifies Multiple Myeloma Patients Likely to Benefit from CAR-T Immunotherapy

Multiple myeloma, a type of blood cancer originating from plasma cells in the bone marrow, sees almost all patients experiencing a relapse at some stage. This means that the cancer returns even after initially... Read more

Microbiology

view channel
Image: Ultra-Rapid Antimicrobial Susceptibility Testing (uRAST) revolutionizing traditional antibiotic susceptibility testing (Photo courtesy of Seoul National University)

Ultra-Rapid Culture-Free Sepsis Test Reduces Testing Time from Days to Hours

Sepsis, a critical emergency condition, results from an overactive inflammatory response to pathogens like bacteria or fungi in the blood, leading to organ damage and the possibility of sudden death.... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.